Last reviewed · How we verify
NRD135SE.1
At a glance
| Generic name | NRD135SE.1 |
|---|---|
| Also known as | NRD135s.E1, a small chemical entity for treatment of neuropathic pain |
| Sponsor | James P. Rathmell, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRD135SE.1 CI brief — competitive landscape report
- NRD135SE.1 updates RSS · CI watch RSS
- James P. Rathmell, MD portfolio CI